½ÃÀ庸°í¼­
»óǰÄÚµå
1503377

Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, ¸ð´Þ¸®Æ¼º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®

Intravascular Ultrasound Devices Market Forecasts to 2030 - Global Analysis By Product, Modality, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀåÀº 2024³â¿¡ 25¾ï 9,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ Áß CAGRÀº 7.1%·Î, 2030³â¿¡´Â 45¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) Àåºñ´Â ½ÉÀå Ä«Å×ÅÍ ½Ã¼ú½Ã »ç¿ëµÇ´Â ÀÇ·á±â±â·Î Ç÷°ü ³»ºÎÀÇ »ó¼¼ÇÑ ¿µ»óÀ» Á¦°øÇÕ´Ï´Ù. IVUS´Â Ç÷°ü ³»¿¡ »ðÀÔµÈ Ä«Å×ÅÍ¿¡ ºÎÂøµÈ ÀÛÀº ÇÁ·Îºê¿¡¼­ ³ª¿À´Â °íÁÖÆÄ À½ÆÄ¸¦ ÀÌ¿ëÇÏ¿© Ç÷°ü º®À» ½Ç½Ã°£À¸·Î ½Ã°¢È­ÇÏ¿© ÇöóÅ© ÃàÀûÀ» °¨ÁöÇϰí, Ç÷°üÀÇ Ä¡¼ö¸¦ Æò°¡Çϰí, Ä¡·á °èȹÀ» ¼¼¿ì´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ½ºÅÙÆ®»ðÀÔ¼ú, Á׻󵿸ÆÀýÁ¦¼ú ¶Ç´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â ´Ù¸¥ Ä¡·á¹ý¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)¿¡ µû¸£¸é ¸Å³â ¾à 805,000¸íÀÇ ¹Ì±¹ÀÎÀÌ ½ÉÀ帶ºñ¸¦ °æÇèÇϰí ÀÖÀ¸¸ç, ÀÌ Áß 605,000¸íÀÌ Ã³À½ ½ÉÀ帶ºñ¸¦ °æÇèÇϰí 200,000¸íÀÌ ÀÌ¹Ì ½ÉÀ帶ºñ¸¦ °æÇèÇÑ »ç¶÷¿¡°Ô¼­ ¹ßº´ÇÑ´Ù°í ÇÕ´Ï´Ù.

Áõ°¡ÇÏ´Â ½ÉÇ÷°ü°è Áúȯ

IVUS Àåºñ´Â Ç÷°ü ³»ºÎ¸¦ »ó¼¼ÇÏ°Ô ¿µ»óÈ­ÇÏ¿© ½ÉÇ÷°ü ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, IVUS ±â¼úÀ» ÅëÇØ ÇöóÅ© ÃàÀû°ú µ¿¸ÆÀÇ Å©±â¸¦ Á¤È®ÇÏ°Ô Æò°¡ÇÒ ¼ö ÀÖÀ¸¸ç, Á¤È®ÇÑ Ä¡·á ¹æÄ§À» °áÁ¤Çϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÇ·áÁøÀÌ ½ÉÇ÷°ü ÁúȯÀÇ Á¶±â ¹ß°ß°ú °³ÀÔÀ» Á¡Á¡ ´õ ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, IVUS Àåºñ ½ÃÀåÀº ±â¼ú ¹ßÀü°ú ÀÇ·áÁøÀÇ ÀÎ½Ä Çâ»ó¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

Àϰü¼º ¾ø´Â »óȯ Á¤Ã¥

Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) ±â±â´Â Áö¿ª°ú ÀÇ·á½Ã½ºÅÛ¿¡ µû¶ó ±ÔÁ¦¿Í Á¤Ã¥ÀÌ ´Ù¸£±â ¶§¹®¿¡ Àϰü¼º ¾ø´Â »óȯ Á¤Ã¥ÀÌ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àϰü¼º ºÎÁ·Àº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô »óȯ ÀÚ°Ý ¹× ºñÀ²¿¡ ´ëÇÑ ºÒÈ®½Ç¼ºÀ» °¡Á®¿Í IVUS ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ¸íÈ®ÇÑ °æÁ¦Àû Àμ¾Æ¼ºê°¡ ¾ø´Ù¸é IVUS ±â±â äÅÃÀ» ÁÖÀúÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÇコÄɾî ÀÎÇÁ¶ó È®´ë

ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë´Â ÷´Ü ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ô¿© Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã¼³ÀÇ °³¼±À¸·Î ´õ ¸¹Àº º´¿ø ¹× Ŭ¸®´Ð¿¡¼­ IVUS ±â±â¸¦ µµÀÔÇÏ¿© Áø´Ü ´É·Â°ú ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÎÇÁ¶ó È®´ë·Î ÀÎÇØ ÀÇ·áÁø¿¡ ´ëÇÑ ±³À° ±âȸ°¡ ´Ã¾î³ª¸é¼­ IVUS ±â¼ú äÅ÷üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

°í°¡ÀÇ IVUS Àåºñ ¹× ½Ã¼ú

IVUS Àåºñ ¹× ½Ã¼úÀÇ ³ôÀº ºñ¿ëÀº ÁÖ·Î ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ȯÀÚ°¡ Á÷¸éÇÑ °æÁ¦Àû Á¦¾àÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î, IVUS Àåºñ ±¸¸Å¿¡ ÇÊ¿äÇÑ Ãʱâ ÅõÀÚ ºñ¿ëÀÌ ³ô±â ¶§¹®¿¡ ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­´Â µµÀÔÀÌ Á¦Çѵ˴ϴÙ. ¶ÇÇÑ IVUS ½Ã¼ú¿¡ µå´Â ºñ¿ëÀº ȯÀڵ鿡°Ô Å« ºÎ´ãÀ¸·Î ÀÛ¿ëÇÏ¿© ¼ö¿ä¸¦ °¨¼Ò½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº °í±Þ Áø´Ü ´É·Â°ú Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ°í ½ÃÀå È®´ë¸¦ ¹æÇØÇϰí ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19 ÆÒµ¥¹ÍÀº ÀÇ·á ÀÚ¿øÀÌ À§±â °ü¸®¸¦ À§ÇØ Àü¿ëµÇ¸é¼­ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, IVUS¸¦ Æ÷ÇÔÇÑ ¼±ÅÃÀû Ä¡·á°¡ ¿¬±âµÇ°Å³ª ÁߴܵǸ鼭 ±â±â »ç¿ë·ü°ú ¸ÅÃâÀÌ °¨¼ÒÇß½À´Ï´Ù. ±×·¯³ª ÀÇ·á ½Ã½ºÅÛÀÌ ÀûÀÀÇÏ°í ¼±ÅÃÀû ¼ö¼úÀÌ Àç°³µÇ¸é¼­ IVUS¿¡ ´ëÇÑ ¼ö¿ä°¡ ȸº¹¼¼·Î µ¹¾Æ¼¹°í, ½ÉÇ÷°ü Áø´Ü ¹× Ä¡·á °èȹ¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇß½À´Ï´Ù. ÀÇ·á ¼­ºñ½º°¡ Á¡Â÷ Á¤»óÈ­µÊ¿¡ µû¶ó ½ÃÀåÀÌ ¾ÈÁ¤È­ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹Ãø ±â°£ Áß IVUS Ä«Å×ÅÍ ºÐ¾ß°¡ °¡Àå Å« ºÐ¾ß°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

IVUS Ä«Å×ÅÍ ºÐ¾ß´Â À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, IVUS Ä«Å×ÅÍ´Â Ç÷°ü ³»ºÎ¸¦ ½Ã°¢È­ÇÏ°í Æò°¡ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. °íÁÖÆÄ À½ÆÄ¸¦ ÀÌ¿ëÇÏ¿© Ç÷°üº®ÀÇ »ó¼¼ÇÑ À̹ÌÁö¸¦ »ý¼ºÇÏ¿© µ¿¸Æ°æÈ­ Á¤µµ, ÇöóÅ© ÇüÅÂ, Ç÷°ü Å©±â¿¡ ´ëÇÑ Áß¿äÇÑ Á¤º¸¸¦ ÀÓ»óÀÇ¿¡°Ô Á¦°øÇÏ´Â IVUS Ä«Å×ÅÍ´Â Ç÷°ü ¼ºÇü¼ú, ½ºÅÙÆ® »ðÀÔ¼ú°ú °°Àº ÁßÀçÀû Ä¡·á¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ç÷°ü ³»ºÎ¿¡¼­ Á÷Á¢ Ç÷°ü º´Å¸¦ Á¤È®ÇÏ°Ô Æò°¡ÇÏ¿© Ä¡·á °á°ú¸¦ ÃÖÀûÈ­ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â ¸»ÃÊÇ÷°ü À̹Ì¡ ºÐ¾ßÀÔ´Ï´Ù.

¸»ÃÊÇ÷°ü À̹Ì¡ ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, IVUS Àåºñ´Â ¸»ÃÊÇ÷°üÀÇ ¿µ»ó Áø´Ü¿¡ µµ¿òÀ» ÁÖ¾î Ç÷°ü ³»ºÎÀÇ °íÇØ»óµµ ½Ã°¢È­¸¦ ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ Àåºñ´Â À½ÆÄ¸¦ »ç¿ëÇÏ¿© »ó¼¼ÇÑ ´Ü¸é À̹ÌÁö¸¦ »ý¼ºÇÏ¿© Ç÷°üÀÇ ÇüÅÂ, ÇöóÅ© ±¸¼º ¹× ÇùÂøÀÇ ½É°¢¼ºÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, IVUS´Â Ç÷°üÀÇ ±¸Á¶¿Í º´¸®ÇÐÀ» ½Ç½Ã°£À¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

°¡Àå ³ôÀº Á¡À¯À²À» º¸ÀÌ´Â Áö¿ª

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ À¯º´·ü Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼±, ÀÇ·áºñ Áõ°¡·Î ÀÎÇØ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áß±¹, ÀϺ», Àεµ¿Í °°Àº ±¹°¡µéÀº ȯÀÚ Àα¸°¡ ¸¹°í ÀÇ·á Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â¼ú ¹ßÀü°ú ÃÖ¼Òħ½ÀÀû ½Ã¼úÀÇ È®´ë´Â IVUS ÀåºñÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

ºÏ¹ÌÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀåÀº Àß ¹ß´ÞµÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº Çõ½Å ÀÇ·á ±â¼ú äÅ÷ü, ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ ³ôÀº ÅõÀÚ·Î ÀÎÇØ ½ÃÀå Á¡À¯À²À» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ȯÀÚ Àα¸°¡ ¸¹°í, ÀÇ·á ÁöÃâÀÌ È°¹ßÇϸç, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç°¨ÀÌ °­ÇØ ½ÃÀå Á¡À¯À²À» ÁÖµµÇϰí ÀÖÀ¸¸ç, ½ÉÇ÷°ü ÁúȯÀÇ Áø´Ü ¹× Ä¡·á¿¡ IVUS ±â±â°¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3»ç)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(ÃÖ´ë 3»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤Ä¡, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¿ªÀû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç ¾îÇÁ·ÎÄ¡
  • Á¶»ç Á¤º¸¿ø
    • 1Â÷ Á¶»ç Á¤º¸¿ø
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå : Á¦Ç°º°

  • IVUS ÄܼÖ/À̹Ì¡ ½Ã½ºÅÛ
  • IVUS Ä«Å×ÅÍ
  • IVUS ¾×¼¼¼­¸®
  • IVUS ¼ÒÇÁÆ®¿þ¾î
  • FFR(ºÐȹÇ÷·ù¿¹ºñ·Â)À» °®Ãá IVUS ½Ã½ºÅÛ
  • IVUS °¡À̵å¿ÍÀ̾î
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå : ¸ð´Þ¸®Æ¼º°

  • °¡»ó Á¶Á÷ÇÐ IVUS(VH-IVUS)
  • ÅëÇÕ ÈĹæ»ê¶õ IVUS(IB-IVUS)
  • Á֯ļö ¿µ¿ª IVUS(FD-IVUS)
  • ½Ã°£ ¿µ¿ª IVUS(TD-IVUS)
  • °ü»óµ¿¸Æ ¾È µµÇ÷¯ IVUS
  • ±¤ °£¼· ´ÜÃþÃÔ¿µ(OCT) IVUS
  • ±ÙÀû¿Ü¼± ºÐ±¤¹ý(NIRS) IVUS
  • ±âŸ ¸ð´Þ¸®Æ¼

Á¦7Àå ¼¼°èÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå : ¿ëµµº°

  • °ü»óµ¿¸Æ ¿µ»ó
  • ¸»ÃÊÇ÷°ü ¿µ»ó
  • Ç÷°ü³» ¿µ»ó
  • ÀÌ½Ä ¿µ»ó
  • ±âŸ ¿ëµµ

Á¦8Àå ¼¼°èÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø¡¤Å¬¸®´Ð
  • ¿µ»ó Áø´Ü ¼¾ÅÍ
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)
  • ¿¬±¸±â°ü
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ¼¼°èÀÇ Ç÷°ü³»ÃÊÀ½ÆÄ(IVUS) µð¹ÙÀ̽º ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕº´»ç¾÷
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Boston Scientific Corporation
  • Philips Healthcare
  • Abbott Laboratories
  • Terumo Corporation
  • Siemens Healthineers
  • Medtronic plc
  • GE Healthcare
  • Provisio Medical Inc.
  • Avinger Inc.
  • Infraredx Inc.
  • Evident Vascular
  • Nipro Corporation
  • Koninklijke Philips N.V.
  • Samsung Medison
  • Esaote SpA
  • Volcano Corporation
KSA 24.07.04

According to Stratistics MRC, the Global Intravascular Ultrasound (IVUS) Devices Market is accounted for $2.59 billion in 2024 and is expected to reach $4.52 billion by 2030 growing at a CAGR of 7.1% during the forecast period. Intravascular ultrasound (IVUS) devices are medical instruments used during cardiac catheterization procedures to provide detailed images of blood vessel interiors. These devices utilize high-frequency sound waves emitted from a tiny probe attached to a catheter, which is inserted into the blood vessel. IVUS enables real-time visualization of the vessel walls, detecting plaque buildup, assessing vessel dimensions, and aiding in treatment planning. IVUS helps cardiologists make informed decisions regarding stenting, atherectomy, or other interventions to improve patient outcomes.

According to the Centers for Disease Control and Prevention (CDC), each year, about 805,000 Americans experience a heart attack; 605,000 of those heart attacks are the first ones and 200,000 occur in individuals who have already experienced one, and 1 in 5 heart attacks are silent.

Market Dynamics:

Driver:

Growing incidenceof cardiovascular diseases

IVUS devices play a crucial role in diagnosing and managing cardiovascular conditions by providing detailed imaging of blood vessels from within. IVUS technology enables precise assessment of plaque buildup and artery dimensions, aiding in accurate treatment decisions and improving patient outcomes. As healthcare providers increasingly prioritize early detection and intervention for cardiovascular diseases, the IVUS devices market continues to expand, driven by advancements in technology and rising awareness among healthcare professionals.

Restraint:

Inconsistent reimbursement policies

Inconsistent reimbursement policies in intravascular ultrasound (IVUS) devices arise due to varying regulations and criteria across different regions or healthcare systems. These inconsistencies create uncertainty for healthcare providers regarding reimbursement eligibility and rates, potentially deterring investment in IVUS technology. Providers may hesitate to adopt IVUS devices without clear financial incentives, limiting market expansion.

Opportunity:

Expanding healthcare infrastructure

Expanding healthcare infrastructure supports the growth of the intravascular ultrasound (IVUS) devices market by facilitating greater accessibility to advanced medical technologies. Improved healthcare facilities enable more hospitals and clinics to adopt IVUS devices, enhancing diagnostic capabilities and patient outcomes. Additionally, infrastructure expansion includes increased training opportunities for healthcare professionals, boosting the adoption rate of IVUS technology.

Threat:

Expensive IVUS equipment and procedures

The high cost of IVUS equipment and procedures hampers market growth primarily due to financial constraints faced by healthcare providers and patients. The initial investment required for purchasing IVUS equipment is substantial, limiting adoption, especially in resource-constrained regions. Moreover, the cost of IVUS procedures can be prohibitive for patients, reducing demand. These factors hinder market expansion by restricting access to advanced diagnostic capabilities and innovative treatment options.

Covid-19 Impact

The covid-19 pandemic significantly impacted the intravascular ultrasound (IVUS) devices market as healthcare resources were diverted to manage the crisis. Elective procedures, including those using IVUS, were postponed or cancelled, leading to a decline in device utilization and sales. However, as healthcare systems adapted and resumed elective surgeries, IVUS demand began recovering, driven by its essential role in cardiovascular diagnostics and treatment planning. The market is expected to stabilize as healthcare services gradually return to normalcy.

The IVUS catheters segment is expected to be the largest during the forecast period

The IVUS catheters segment is estimated to have a lucrative growth. IVUS catheters are medical devices used to visualize and assess the interior of blood vessels. They employ high-frequency sound waves to generate detailed images of vessel walls, providing clinicians with crucial insights into the extent of atherosclerosis, plaque morphology, and vessel dimensions. IVUS catheters play a pivotal role in guiding interventional procedures like angioplasty and stent placement, helping to optimize treatment outcomes by enabling precise assessment of vessel pathology directly from within the artery.

The peripheral vascular imaging segment is expected to have the highest CAGR during the forecast period

The peripheral vascular imaging segment is anticipated to witness the fastest CAGR growth during the forecast period. IVUS devices are instrumental in peripheral vascular imaging, facilitating high-resolution visualization of blood vessel interiors. These devices utilize sound waves to produce detailed cross-sectional images, aiding in the assessment of vessel morphology, plaque composition, and stenosis severity. IVUS devices offer real-time insights into vessel structure and pathology.

Region with largest share:

In the Asia-Pacific region, the Intravascular Ultrasound (IVUS) Devices market is experiencing growth driven by increasing cardiovascular disease prevalence, improving healthcare infrastructure, and rising healthcare expenditure. Countries like China, Japan, and India are key contributors to this growth due to their large patient populations and expanding healthcare access. Additionally, technological advancements and greater adoption of minimally invasive procedures are boosting IVUS device utilization.

Region with highest CAGR:

In North America, the Intravascular Ultrasound (IVUS) Devices market is well-established and characterized by advanced healthcare infrastructure, high adoption rates of innovative medical technologies, and significant investments in research and development. The United States leads in market share due to its large patient population, robust healthcare spending, and strong presence of key market players. IVUS devices are widely used in the diagnosis and treatment of cardiovascular diseases, driving market growth.

Key players in the market

Some of the key players profiled in the Intravascular Ultrasound (IVUS) Devices Market include Boston Scientific Corporation, Philips Healthcare, Abbott Laboratories, Terumo Corporation, Siemens Healthineers, Medtronic plc, GE Healthcare, Provisio Medical Inc., Avinger Inc., Infraredx Inc., Evident Vascular, Nipro Corporation, Koninklijke Philips N.V., Samsung Medison, Esaote SpA, Volcano Corporation

Key Developments:

In May 2024, Provisio Medical, Inc., announced the completion of the first commercial clinical cases utilizing the Provisio SLT intravascular ultrasound (IVUS) system.It gives rapid, novel, and extremely precise way to get the size and contour of vessels, which is critical for the appropriate treatment of a patient with chronic and limb threatening ischemia.

In October2023, Evident Vascular has launched IVUS transcatheterwith $35m in Series A financing from Vensana Capital for the development of an intravascular ultrasound (IVUS) platform. It is designed to capture images from inside blood vessels to assess vascular disease and guide interventional treatment.

Products Covered:

  • IVUS Consoles/Imaging Systems
  • IVUS Catheters
  • IVUS Accessories
  • IVUS Software
  • IVUS Systems with FFR (Fractional Flow Reserve)
  • IVUS Guidewires
  • Other Products

Modalities Covered:

  • Virtual Histology IVUS (VH-IVUS)
  • Integrated Backscatter IVUS (IB-IVUS)
  • Frequency Domain IVUS (FD-IVUS)
  • Time Domain IVUS (TD-IVUS)
  • Intracoronary Doppler IVUS
  • Optical Coherence Tomography (OCT) IVUS
  • Near-infrared Spectroscopy (NIRS) IVUS
  • Other Modalities

Applications Covered:

  • Coronary Imaging
  • Peripheral Vascular Imaging
  • Endovascular Imaging
  • Transplant Imaging
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Imaging Centers
  • Ambulatory Surgical Centers (ASCs)
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Intravascular Ultrasound (IVUS) Devices Market, By Product

  • 5.1 Introduction
  • 5.2 IVUS Consoles/Imaging Systems
  • 5.3 IVUS Catheters
  • 5.4 IVUS Accessories
  • 5.5 IVUS Software
  • 5.6 IVUS Systems with FFR (Fractional Flow Reserve)
  • 5.7 IVUS Guidewires
  • 5.8 Other Products

6 Global Intravascular Ultrasound (IVUS) Devices Market, By Modality

  • 6.1 Introduction
  • 6.2 Virtual Histology IVUS (VH-IVUS)
  • 6.3 Integrated Backscatter IVUS (IB-IVUS)
  • 6.4 Frequency Domain IVUS (FD-IVUS)
  • 6.5 Time Domain IVUS (TD-IVUS)
  • 6.6 Intracoronary Doppler IVUS
  • 6.7 Optical Coherence Tomography (OCT) IVUS
  • 6.8 Near-infrared Spectroscopy (NIRS) IVUS
  • 6.9 Other Modalities

7 Global Intravascular Ultrasound (IVUS) Devices Market, By Application

  • 7.1 Introduction
  • 7.2 Coronary Imaging
  • 7.3 Peripheral Vascular Imaging
  • 7.4 Endovascular Imaging
  • 7.5 Transplant Imaging
  • 7.6 Other Applications

8 Global Intravascular Ultrasound (IVUS) Devices Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Imaging Centers
  • 8.4 Ambulatory Surgical Centers (ASCs)
  • 8.5 Research Institutes
  • 8.6 Other End Users

9 Global Intravascular Ultrasound (IVUS) Devices Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Boston Scientific Corporation
  • 11.2 Philips Healthcare
  • 11.3 Abbott Laboratories
  • 11.4 Terumo Corporation
  • 11.5 Siemens Healthineers
  • 11.6 Medtronic plc
  • 11.7 GE Healthcare
  • 11.8 Provisio Medical Inc.
  • 11.9 Avinger Inc.
  • 11.10 Infraredx Inc.
  • 11.11 Evident Vascular
  • 11.12 Nipro Corporation
  • 11.13 Koninklijke Philips N.V.
  • 11.14 Samsung Medison
  • 11.15 Esaote SpA
  • 11.16 Volcano Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦